These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
691 related articles for article (PubMed ID: 31171029)
1. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial. Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW; Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029 [TBL] [Abstract][Full Text] [Related]
2. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Hagel S; Bach F; Brenner T; Bracht H; Brinkmann A; Annecke T; Hohn A; Weigand M; Michels G; Kluge S; Nierhaus A; Jarczak D; König C; Weismann D; Frey O; Witzke D; Müller C; Bauer M; Kiehntopf M; Neugebauer S; Lehmann T; Roberts JA; Pletz MW; Intensive Care Med; 2022 Mar; 48(3):311-321. PubMed ID: 35106617 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974 [TBL] [Abstract][Full Text] [Related]
4. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514 [TBL] [Abstract][Full Text] [Related]
5. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients. Schoenenberger-Arnaiz JA; Ahmad-Diaz F; Miralbes-Torner M; Aragones-Eroles A; Cano-Marron M; Palomar-Martinez M Eur J Hosp Pharm; 2020 Mar; 27(e1):e30-e35. PubMed ID: 32296502 [TBL] [Abstract][Full Text] [Related]
6. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898 [TBL] [Abstract][Full Text] [Related]
7. Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial. Bloos F; Trips E; Nierhaus A; Briegel J; Heyland DK; Jaschinski U; Moerer O; Weyland A; Marx G; Gründling M; Kluge S; Kaufmann I; Ott K; Quintel M; Jelschen F; Meybohm P; Rademacher S; Meier-Hellmann A; Utzolino S; Kaisers UX; Putensen C; Elke G; Ragaller M; Gerlach H; Ludewig K; Kiehntopf M; Bogatsch H; Engel C; Brunkhorst FM; Loeffler M; Reinhart K; JAMA Intern Med; 2016 Sep; 176(9):1266-76. PubMed ID: 27428731 [TBL] [Abstract][Full Text] [Related]
8. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion. Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627 [TBL] [Abstract][Full Text] [Related]
9. PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA. Solórzano-Santos F; Quezada-Herrera A; Fuentes-Pacheco Y; Rodríguez-Coello G; Aguirre-Morales CE; Izelo-Flores D; Muñoz-Hernández O; Miranda-Novales MG; Labra-Zamora MG Rev Invest Clin; 2019; 71(4):283-290. PubMed ID: 31448789 [TBL] [Abstract][Full Text] [Related]
10. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure? Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869 [TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children. Thibault C; Lavigne J; Litalien C; Kassir N; Théorêt Y; Autmizguine J Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427292 [TBL] [Abstract][Full Text] [Related]
12. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F; J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562 [TBL] [Abstract][Full Text] [Related]
13. Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Gatti M; Bonazzetti C; Pascale R; Giannella M; Viale P; Pea F Microorganisms; 2024 Jan; 12(1):. PubMed ID: 38257978 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. De Waele JJ; Carrette S; Carlier M; Stove V; Boelens J; Claeys G; Leroux-Roels I; Hoste E; Depuydt P; Decruyenaere J; Verstraete AG Intensive Care Med; 2014 Mar; 40(3):380-7. PubMed ID: 24356862 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872 [TBL] [Abstract][Full Text] [Related]
16. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Cojutti PG; Pai MP; Tonetti T; Siniscalchi A; Viale P; Pea F Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140423. PubMed ID: 38411995 [TBL] [Abstract][Full Text] [Related]
17. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J; Am J Respir Crit Care Med; 2015 Dec; 192(11):1298-305. PubMed ID: 26200166 [TBL] [Abstract][Full Text] [Related]
18. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion. Carrié C; Legeron R; Petit L; Ollivier J; Cottenceau V; d'Houdain N; Boyer P; Lafitte M; Xuereb F; Sztark F; Breilh D; Biais M J Crit Care; 2018 Dec; 48():66-71. PubMed ID: 30172963 [TBL] [Abstract][Full Text] [Related]
19. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis. Rhodes NJ; Liu J; O'Donnell JN; Dulhunty JM; Abdul-Aziz MH; Berko PY; Nadler B; Lipman J; Roberts JA Crit Care Med; 2018 Feb; 46(2):236-243. PubMed ID: 29116995 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). Laporte-Amargos J; Gudiol C; Arnan M; Puerta-Alcalde P; Carmona-Torre F; Huguet M; Albasanz-Puig A; Parody R; Garcia-Vidal C; Del Pozo JL; Batlle M; Tebé C; Rigo-Bonnin R; Muñoz C; Padullés A; Tubau F; Videla S; Sureda A; Carratalà J Trials; 2020 May; 21(1):412. PubMed ID: 32423462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]